Display options
Cite
Villa NY, Rahman MM, Mamola J, et al. Autologous Transplantation Using Donor Leukocytes Loaded . Mol Ther Oncolytics. 2020;18:171-188doi: 10.1016/j.omto.2020.06.011.
Villa, N. Y., Rahman, M. M., Mamola, J., D'Isabella, J., Goras, E., Kilbourne, J., Lowe, K., Daggett-Vondras, J., Torres, L., Christie, J., Appel, N., Cox, A. L., Kim, J. B., & McFadden, G. (2020). Autologous Transplantation Using Donor Leukocytes Loaded . Molecular therapy oncolytics, 18171-188. https://doi.org/10.1016/j.omto.2020.06.011
Villa, Nancy Y, et al. "Autologous Transplantation Using Donor Leukocytes Loaded ." Molecular therapy oncolytics vol. 18 (2020): 171-188. doi: https://doi.org/10.1016/j.omto.2020.06.011
Villa NY, Rahman MM, Mamola J, D'Isabella J, Goras E, Kilbourne J, Lowe K, Daggett-Vondras J, Torres L, Christie J, Appel N, Cox AL, Kim JB, McFadden G. Autologous Transplantation Using Donor Leukocytes Loaded . Mol Ther Oncolytics. 2020 Jun 24;18:171-188. doi: 10.1016/j.omto.2020.06.011. eCollection 2020 Sep 25. PMID: 32695875; PMCID: PMC7364119.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Oncolytics. 2020 Jun 24;18:171-188. doi: 10.1016/j.omto.2020.06.011. eCollection 2020 Sep 25.

Autologous Transplantation Using Donor Leukocytes Loaded .

Molecular therapy oncolytics

Nancy Y Villa, Masmudur M Rahman, Joseph Mamola, Julia D'Isabella, Elizabeth Goras, Jacquelyn Kilbourne, Kenneth Lowe, Juliane Daggett-Vondras, Lino Torres, John Christie, Nicole Appel, Anna L Cox, Jae B Kim, Grant McFadden

Affiliations

  1. Biodesign Institute, Center for Immunotherapy, Vaccines and Virotherapy (CIVV), Arizona State University, Tempe, AZ 85281, USA.
  2. PerkinElmer Inc., Waltham, MA 02451, USA.

PMID: 32695875 PMCID: PMC7364119 DOI: 10.1016/j.omto.2020.06.011

Abstract

Multiple myeloma (MM) is a hematological malignancy of monoclonal plasma cells that remains incurable. Standard treatments for MM include myeloablative regimens and autologous cell transplantation for eligible patients. A major challenge of these treatments is the relapse of the disease due to residual MM in niches that become refractory to treatments. Therefore, novel therapies are needed in order to eliminate minimal residual disease (MRD). Recently, our laboratory reported that virotherapy with oncolytic myxoma virus (MYXV) improved MM-free survival in an allogeneic transplant mouse model. In this study, we demonstrate the capacity of donor autologous murine leukocytes, pre-armed with MYXV, to eliminate MRD in a BALB/c MM model. We report that MYXV-armed bone marrow (BM) carrier leukocytes are therapeutically superior to MYXV-armed peripheral blood mononuclear cells (PBMCs) or free virus. Importantly, when cured survivor mice were re-challenged with fresh myeloma cells, they developed immunity to the same MM that had comprised MRD.

© 2020 The Author(s).

Keywords: autologous stem cells transplantation (ASCT); carrier cells; minimal residual disease (MRD); multiple myeloma (MM); myxoma virus (MYXV); tumor micreoenvironment (TME)

References

  1. Vaccine. 2013 Sep 6;31(39):4252-8 - PubMed
  2. Front Immunol. 2018 Apr 26;9:866 - PubMed
  3. Blood. 2011 May 26;117(21):5573-81 - PubMed
  4. Cancer Res. 2017 Apr 15;77(8):2052-2063 - PubMed
  5. Expert Opin Biol Ther. 2007 Sep;7(9):1415-25 - PubMed
  6. Cancer Gene Ther. 2010 Jul;17(7):476-83 - PubMed
  7. Gene Ther. 2008 May;15(10):797-806 - PubMed
  8. N Engl J Med. 2004 Oct 28;351(18):1860-73 - PubMed
  9. Ther Adv Hematol. 2019 Nov 14;10:2040620719888111 - PubMed
  10. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):1-7 - PubMed
  11. Mol Ther Oncolytics. 2016 Dec 14;4:31-40 - PubMed
  12. Cell Rep. 2016 Apr 12;15(2):264-73 - PubMed
  13. Cancers (Basel). 2019 May 11;11(5): - PubMed
  14. J Virol. 2009 Aug;83(16):8108-21 - PubMed
  15. Cancers (Basel). 2019 Dec 13;11(12): - PubMed
  16. Nat Rev Drug Discov. 2015 Sep;14(9):642-62 - PubMed
  17. Nat Rev Cancer. 2007 Aug;7(8):585-98 - PubMed
  18. Mol Ther Oncolytics. 2016 Dec 07;3:16032 - PubMed
  19. Cancer Lett. 2016 Feb 28;371(2):161-70 - PubMed
  20. Br J Haematol. 2019 Sep;186(6):807-819 - PubMed
  21. PLoS One. 2007 Oct 24;2(10):e1075 - PubMed
  22. Mol Ther Oncolytics. 2019 Nov 29;16:41-52 - PubMed
  23. Nat Rev Cancer. 2005 Apr;5(4):263-74 - PubMed
  24. Blood. 2014 May 22;123(21):3305-15 - PubMed
  25. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30-e37 - PubMed
  26. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):169-75 - PubMed
  27. Adv Virol. 2012;2012:186512 - PubMed
  28. Biol Blood Marrow Transplant. 2012 Oct;18(10):1540-51 - PubMed
  29. Sci Transl Med. 2014 Mar 5;6(226):226ra32 - PubMed
  30. Cancer Res. 2019 Sep 1;79(17):4503-4514 - PubMed
  31. Immunotherapy. 2015;7(6):611-9 - PubMed
  32. Int J Cancer. 2019 Oct 1;145(7):1958-1969 - PubMed
  33. Neuro Oncol. 2016 Mar 8;18(8):1088-1098 - PubMed
  34. Oncolytic Virother. 2018 Feb 23;7:1-12 - PubMed
  35. Blood. 2015 Jun 11;125(24):3778-88 - PubMed
  36. Lancet Oncol. 2016 Aug;17(8):e328-e346 - PubMed
  37. Cancers (Basel). 2018 Jun 14;10(6): - PubMed
  38. Semin Oncol Nurs. 2017 Aug;33(3):225-236 - PubMed
  39. Leukemia. 2009 Mar;23(3):435-41 - PubMed
  40. N Engl J Med. 2011 Mar 17;364(11):1046-60 - PubMed
  41. Nat Rev Immunol. 2018 Aug;18(8):498-513 - PubMed
  42. Lancet Haematol. 2019 Dec;6(12):e600-e601 - PubMed
  43. Nat Med. 2016 Dec;22(12):1411-1420 - PubMed
  44. Expert Rev Anticancer Ther. 2019 Oct;19(10):889-898 - PubMed
  45. Front Oncol. 2019 Aug 20;9:699 - PubMed
  46. Biomedicines. 2017 Feb 10;5(1): - PubMed
  47. Mol Cancer Ther. 2019 Jan;18(1):127-138 - PubMed

Publication Types